IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas

IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas Maggie Seblani, Markella Zannikou, Joseph Duffy, Rebecca Levine, and 7 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5398280/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 02 Apr, 2025 Read the published version in Acta Neuropathologica Communications → Version 1 posted 7 You are reading this latest preprint version Abstract Pediatric high-grade gliomas (pHGG) and pediatric diffuse midline gliomas (pDMG) are devastating diseases without durable and curative options. Although targeted immunotherapy has shown promise, the field lacks immunocompetent animal models to study these processes in detail. To achieve this, we developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, interleukin 13 receptor alpha 2 (IL13RA2). Utilizing the RCAS-Tva delivery system in Nestin-Tva mice, we induced gliomagenesis by overexpressing PDGFB and deleting p53 (p53 fl/fl ) or both p53 and PTEN (p53 fl/fl PTEN fl/fl ), with or without IL13RA2 in neonatal mice. De novo tumors developed in models with and without IL13RA2, showing no statistical difference in onset (n = 33, 38 days, p = 0.62). The p53 fl/fl PTEN fl/fl tumors displayed more aggressive characteristics (n = 12, 31 days). Tumors exhibited features typical of high-grade glioma, including infiltration, pseudopalisading necrosis, and microvascular proliferation. They also showed a high Ki-67 index, variable IL13RA2 expression, a high frequency of CD11b + macrophages, and a low proportion of CD3 + T cells. The model proved effective for evaluating IL13RA2-targeted immunotherapies, with a significant response to CAR T-cell treatment that extended survival (46 days vs. 28 days control; p < 0.0001) and achieved 25% long-term survival in mice. This model facilitates the preclinical assessment of IL13RA2-directed therapies and holds potential for clinical application. Figures Figure 1 Figure 2 Figure 3 Figure 4 INTRODUCTION Among pediatric cancers, diffuse midline gliomas (DMG) are notorious for their universally poor outcomes 1 . The prototypical diffuse midline glioma, diffuse intrinsic pontine glioma (DIPG), is an aggressive tumor that has a median survival of less than one year from diagnosis and is currently incurable 2 . Radiation provides limited symptom control and extends overall survival on average by only three months. The lack of sustained response to conventional therapies reinforces the pressing need for new therapies. 3 , 4 The recent success of cancer immunotherapy in adults and children with hematologic malignancies has intensified efforts to develop immunomodulatory applications in central nervous system (CNS) tumors. Advances in molecular characterization of midline gliomas via increased tissue sampling at diagnosis and post-mortem have enabled the subgrouping of tumors and identified molecular drivers 1 , 5 – 7 . Surface markers, such as GD2 and B7-H3, have previously been characterized based on expression levels and degree of inter- and intra-patient heterogeneity 8 , 9 . Preclinical studies of chimeric antigen receptor-modified T-cells (CAR T-cells) targeting GD2 and B7-H3 (CD276) have translated into clinical trials (NCT04196413, NCT04099797, NCT04185038) 10 , 11 . Interleukin-13 receptor alpha 2 (IL13RA2) is another attractive immunotherapeutic target in pediatric HGG (pHGG). High expression of IL13RA2 has been described in DIPG and other pHGG tissues 4 , 12 , 13 . Within adult-type diffuse gliomas, IL13RA2 targeting therapies have been the focus of multiple preclinical and clinical studies. One study utilized the IL13RA2 epitope for a glioma vaccine 14 , and a phase I clinical trial featuring IL13RA2 targeting CAR T-cells in IL13RA2-positive glioblastoma in adults has been recently completed 15 . Autologous CAR T-cells targeting IL13RA2 in patients with recurrent or refractory pHGG are currently being evaluated (NCT04510051). Overall, the advancements in molecular characterization, cellular engineering capabilities, and the growing number of clinical trials justify the investigation of targeted immunotherapy for DMG. Orthotopic implantation of murine glioma cell lines into immunocompetent hosts is predominantly used for preclinical evaluation of targeted immunotherapies. However, the inability of these models to recapitulate the tumor microenvironment and failure to express targetable human antigens remains a limitation for clinical translation. Therefore, developing an immunocompetent preclinical model which both recapitulates DMG and expresses targetable human antigens is paramount. Although these advances provide a growing number of targets for immunotherapy and justify further investigation into IL13RA2 as a target, the lack of an immunocompetent preclinical model of DIPG that expresses human IL13RA2 hinders the development of IL13RA2-directed immunotherapies. A genetically engineered mouse model (GEMM) is one such system that permits tumorigenesis in the presence of a competent immune system 13 , 16 . GEMMs enable the spatiotemporal introduction of specific genetic abnormalities and permit the investigation of various stages of tumor development, including tumor initiation 17 . The RCAS/Tva system is a powerful genetic engineering tool that enables specific somatic cell gene transfer into cells engineered to express the Tva receptor 18 . Holland and colleagues previously developed GEMM, which uses the RCAS/Tva system to delete p53 in Tva-positive cells and induce gliomagenesis 18 . Using engineered mice with Tva receptors in nestin-positive progenitor cells, a candidate cell of origin for DIPG 19 , 20 , Becher and colleagues expanded this model to induce brainstem gliomogenesis in newborn mice 21 . The strength of this model is in its versatility, as it enables customization to express exogenous human genes of interest, namely immunotherapeutic targets, within Tva-expressing cells. We have previously developed an IL13RA2-specific antibody and incorporated it into CAR T-cells and bi-specific T-cell engagers for preclinical evaluation in adult glioblastoma 22 , 23 . Here, we integrated IL13RA2 into a construct encoding for PDGFB and used the RCAS/Tva system to develop a novel immunocompetent GEMM that both recapitulates diffuse midline gliomas and expresses the human glioma-associated antigen IL13RA2. We tested the feasibility of this model to assess the anti-tumor efficacy of our IL13RA2-CAR T-cells. Engineering diffuse midline and hemispheric high-grade gliomas that express IL13RA2 will fill a significant gap in existing models and allow preclinical mechanistic and therapeutic studies in corresponding pediatric brain tumors. MATERIALS and METHODS Analysis of TCGA patient data sets Levels of IL13RA2 gene expression in pediatric brain tumors were assessed using a publicly available microarray expression profile Gump database (tumor samples: 106, non-tumor: 6; GEO ID: GSE68015). RNA-seq data from Gump were visualized using GlioVis ( http://gliovis.bioinfo.cnio.es/ ), with the relative expression of IL13RA2 determined from log2 transformation of normalized count reads. 24 Statistical significance between pediatric tumors was determined using Tukey's Honest Significant Difference (HSD) within GlioVis, with one asterisk (*) where p < 0.05, two (**) where p < 0.01, and three (***) where p < 0.001. Histology and immunohistochemistry of human samples Human tumor samples were initially obtained under Institutional Review Board approved protocol (#IRB 2019–3164) per Ann and Robert H. Lurie Children's Hospital of Chicago. All samples were de-identified. Tissue sections were stained with H&E and for IL13RA2 (R&D antibody, cat AF146) IHC. Scoring was performed independently by a neuropathologist (C.H.). Scores were established on the percent positively labeled tumor cells; 0 is no positivity, 1 is ≤ 10% positive tumor cells, 2 is 10–50% positive tumor cells, 3 is ≥ 50% positive tumor cells. PTEN immunohistochemistry staining was performed on a Leica Bond Rx platform (Leica). Primary anti-PTEN antibodies were diluted 1:100 (Cell Signaling, #9559). Anti-rabbit secondary antibodies were purchased from Leica. Digital slide images were acquired using a Nanozoomer 2.0HT whole-slide scanner (Hamamatsu Photonic K.K.) and observed offline with NDP.view2 software (Hamamatsu). Cell lines and cell culture reagents DF-1 (chicken fibroblast) cell line was obtained from ATCC (cat #CRL-12203). All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Manassas, Virginia; Cat #30-2002) supplemented with 10% fetal bovine serum (FBS) (R&D Systems, Minneapolis, MN), 1% penicillin/streptomycin (P/S) (Corning, Corning, NY; Cat #30-002-CI) and 2mM L-glutamine (Corning, Corning, NY; Cat # 25-005-CI). Dulbecco's Phosphate-buffered saline (PBS) was obtained from Thermo Fisher. GeneJuice was purchased from (Millipore Sigma). Cloning IL13RA2 in vector encoding for PDGFB cDNA The cDNA encoding T2A-IL13RA2 was synthesized by GenScript, subcloned into the RCAS-PDGFB-HA vector 25 following the PDGFB cDNA using CloneEZ method, and verified by Sanger sequencing (GenScript, Piscataway, NJ). The plasmid was amplified in DH5a cells (NewEngland Biolabs, Ipswich, MA; Cat #C2987H) and purified using a plasmid purification midi-kit (Qiagen, Hilden, Germany; Cat # 12145). Generation of DF-1 cells producing virus encoding for PDGFB, RCAS-Cre, and PDGFB + IL13RA2 Our approach expands upon a previously described use of the RCAS-Tva system for GEMM creation. 14 Briefly, we cultured DF-1 cells in optimal growth conditions in DMEM supplemented with 10% FBS, 1% P/S, and 2 mM L-glutamine. Cells were transfected with RCAS plasmids (RCAS-Cre, PDGFB, and PDGFB + IL13Rα) using GeneJuice (Millipore Sigma, Burlington, MA; Cat # 70967), per the manufacturer's protocol. To propagate the necessary cell number and adequate retrovirus for intracranial injection, we serially passaged the three transfected cell groups upon reaching 80–90% density for up to five passages. Generation of CAR T-cells for targeting of IL13RA2-expressing de novo tumors. Murine CAR T-cells targeting IL13RA2 were generated as we previously reported 26 . CAR T-cells were tested for their ability to kill newly generated cell lines in co-culture with newly generated IL13RA2-expressing glioma lines for 48 hours at 1:20 target-to-effector (T:E) ratio. Western blot Cells were cultured in complete DMEM as previously described. Cells were collected, pelleted, and then resuspended into one mL of cold Dulbecco's Phosphate-buffered saline (PBS) (4°C). Cells were counted via the trypan-blue exclusion method, pelleted by centrifugation (400x g, 5 min), and lysed in ice-cold Mammalian Protein Extraction Reagent (mPER) (Thermo Scientific, Waltham, MC) at a concentration of 20,000 cells/µL mPER. Protein concentration was measured using a Pierce ™ bicinchoninic acid (BCA) protein assay kit (Thermo Scientific. Protein samples were then prepared in Laemmli Sample Buffer (Bio-Rad, Hercules, CA; Cat #1610747) with 2.5% 2-Mercaptoethanol (Sigma Aldrich, St. Louis, MO; Cat #M6250) and denatured at 95°C for 5 min. Protein samples and 250 kDa Precision Plus Protein standard (Bio-Rad Laboratories, Hercules, CA) were loaded into each well of a 4–20% Midi-PROTEAN® TGX Stain-Free™ gel (Bio-Rad). Proteins were separated by size using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a methanol-activated 0.2 µm PVDF membrane (Millipore Sigma, Burlington, MA; Cat #IPVH08100) using the Trans-Blot® Turbo Transfer System™ (Bio-Rad). Membranes were blocked with 5% non-fat dry milk (NFDM) in tris-buffered saline plus 0.1% Tween-20 (TBST) (Boston Bioproducts, Ashland, MA; Cat #IBB180) for 2 hours at RT. Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4°C. The next day, membranes were washed with TBST and incubated with anti-rabbit HRP-linked Secondary Antibody (1:1000) (Cell Signaling Technology, 7074) for GAPDH and anti-HA tag and chicken anti-goat Secondary Antibody (Santa Cruz Biotechnology, sc-2953) for IL13RA2. Blots were washed with TBST, incubated with Clarity™ Western ECL Substrate (Bio-Rad), and detected via chemiluminescent image acquired by ChemiDoc™ MP Imaging System (Bio-Rad). Flow Cytometry Cells were maintained in culture with complete DMEM. Cells were collected, pelleted, and incubated with TruStain Fc Blocking Antibody (1:200 in 1% FBS in DPBS) (4°C). Next, 100,000 cells were added to each tissue culture-treated V-bottom plate well. Cells were pelleted and stained on ice with PE anti-human IL13RA2 (Biolegend, 354403). Live cells were labeled with a fixable viability stain (Invitrogen, 65-0865-14). Cells were then fixed, permeabilized, and stained with Alexa-Fluor 488 Anti-HA antibody (Biolegend, 901509) to detect PDGFB. Antibodies against CD45, CD4, CD8, CD69, CD25, Granzyme B, CD44, FoxP3, CD11b, Ly6C and Ly6G (BioLegend) were used for analysis of T-cell activation and myeloid cell presence in tumors environment in response to CAR T-cell treatment. Data acquisition was done using the FACSymphony A5-Laser Analyzer, BD. Histology and immunohistochemistry of mouse samples At selected time points or based upon clinical deterioration, animals were perfused with PBS to collect brain tissue for sectioning. Tissue was fixed in 4% paraformaldehyde (PFA), then paraffin-embedded, cut into 4-micron sections, and stained with hematoxylin and eosin (H&E). Further immunohistochemistry staining was obtained using following antibodies: IL13RA2 (R&D AF146; 1:200), Olig2 (Abcam ab109186; 1:2000), Ki67 (Abcam ab16667; 1:500), CD3 (Abcam ab16669; 1:1000), CD11b (Abcam ab133357; 1:3000). To demonstrate the PTEN and H3K27me3 absence in glioma cells, the staining of tissues was carried out using PTEN (138G6) and Tri-Methyl-Histone H3 (Lys27) rabbit (C36B11, 1:300) antibodies recognizing wild-type PTEN and H3.3 histon proteins (Cell Signaling). Animal Studies Nestin-tva (Ntv-a) p53 fl/fl or Ntv-a p53 fl/fl PTEN fl/fl (obtained from Dr. Becher Laboratory) mice were bred in-house per animal protocols approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC). Our study included male and female mice with no effect of sex as a biological variable being evaluated explicitly in the study. Suspensions of virus-producing cells were injected into the hindbrain of Ntv-a p53 fl/fl mice pups between three to five post-natal days of age, using cryoanesthesia during the procedure. We evaluated two experimental groups: 1) RCAS-PDGFB and 2) RCAS-PDGFB + IL13RA2 with p53 or p53/PTEN loss, with the former as the established model and the latter our new model with a combined cell count of 1-2x10 5 cells/mL per pup (a 1:1 ratio of RCAS-Cre with PDGFB or PDGFB + IL13RA2) suspended in PBS for a total volume of 1.2 µL. In a separate experiment, cells producing RCAS-H3.3 K27M were added to Ntv-a p53 fl/fl PTEN fl/fl model. To generate DIPG-bearing mice, the injection site was approximately 2 mm posterior to the bregma along the midline using a Hamilton syringe and custom needle. Hemispheric tumors were induced by injecting pups about 1 mm posterior to the bregma and 1 mm right of the midline. Upon postprocedural recovery and rewarming, the pups were returned to their nursing mother. Following injection, mice were monitored closely for symptoms consistent with tumor involvement, including ataxia, seizures, enlarged head, and weight loss. For assessment with CAR T-cell therapy, mice bearing de novo cortical tumors were injected with 1 x10 6 of non-transduced control or CAR T-cells in the same coordinates as an original tumor initiation site approximately two weeks after tumor induction. Brains were collected 72 hours post CAR T-cells injection for flow cytometric analysis of infiltrating immune cells. Survival outcomes were monitored, and mice were designated as long-term survivors (LTS) if they demonstrated no signs of disease at a 120-day post-injection interval. Brains of LTS mice were collected and histologically evaluated to confirm tumor absence. Generation of cell lines for orthotopic model Cell lines were generated by processing tumor-bearing tissue obtained from symptomatic mice. Mice were anesthetized with a solution consisting of 200 mg/kg ketamine and 20 mg/kg xylazine and perfused with PBS before neoplastic tissue was processed with the NeuroCult ™ enzymatic dissociation Kit (StemCell Technologies, 05715) per manufacturer's instructions. Cells were maintained as neurospheres in NeuroCult ™ proliferation media (Stem Cell Technologies, Vancouver, Canada; Cat #05072) with the addition of mouse cell proliferation supplement (Stem Cell Technologies, Cat #05701), P/S, heparin at 2µg/mL and 10ng/mL epidermal growth factor, and 20ng/mL basic fibroblast growth factor. For orthotopic experiments, mouse pups were injected with 1 x 10 5 cells (1.2 µL) per animal in the hindbrain and the right cortex, as described in animal studies. Statistics Statistical data analyses were executed using GraphPad 8 (Prism, La Jolla, CA) and Microsoft Excel. Significance was defined as p less than 0.05 in all statistical tests. P values were established as follows: * p < .05, ** p < .01, *** p < .001, and **** p < .0001. As indicated, data in two groups were analyzed for statistical significance using the unpaired Mann-Whitney test or an unpaired two-tailed Student's t-test. One- or two-way ANOVA was used for multiple groups, followed by Tukey's or Dunnett's multiple comparisons test. Animal survival analysis was performed by generating Kaplan-Meier plots using the Wald test to determine the p-value. RESULTS Analysis of IL13RA2 expression in patient tissues IL13RA2 expression in adult-type diffuse high-grade gliomas is well established, and it has been used as an immunotherapeutic target in multiple preclinical and clinical studies. 22 , 23 , 27 , 28 To determine the relative expression in pediatric CNS tumors, we used GlioVis to visualize IL13RA2 gene expression within the publicly available Gump database (GEO ID: GSE68015). Increased IL13RA2 mRNA expression was found in pediatric-type diffuse high-grade gliomas (pHGG) compared to non-neoplastic brain tissue and other pediatric brain tumors (Fig. 1 A). Furthermore, elevated IL13RA2 gene expression was seen in pHGG compared to low-grade CNS tumors (Fig. 1 A). To validate these findings further, we assessed tissue expression of IL13RA2 in twenty post-mortem pediatric DIPG samples using immunohistochemistry (IHC). Nine of the twenty (45%) samples were positive for IL13RA2, receiving histopathological scores of 1 (n = 5), 2 (n = 3), and 3 (n = 1) (Fig. 1 B&C). Generation and characterization of the RCAS-Tva model of high-grade pediatric diffuse glioma expressing IL13RA2 To generate de novo tumors, we first cloned human IL13RA2 in a PDGFB construct using a T2A cleaving peptide. Next, we transfected DF-1 cells with either RCAS-Cre, RCAS-PDGFB, or RCAS-PDGFB + IL13RA2 constructs. Subsequent flow cytometry (FSC) analysis of DF-1 cells showed robust expression of PDGFB (64.1%) and PDGFB + IL13RA2 (64.0%) (Fig. 2 B). Secondary confirmation of successful RCAS-PDGFB and RCAS-PDGFB + IL13RA2 transfection was achieved via western blotting for PDGFB and IL13RA2 (Fig. 2 C). Following transduction confirmation, we evaluated growth dynamics of de novo tumors in vivo by infecting nestin-expressing progenitors in either the midbrain or right cortex of 4–5-day-old Nestin-tva p53 fl/fl mice to model pDMG and pHGG, respectively. No significant changes were noted in the median survival of mice between RCAS-PDGFB (n = 35, 38 days) and RCAS-PDGFB + IL13RA2 (n = 35, 38 days) of pDMG models (Fig. 2 D). Histopathological analysis of de novo tumors, generation of cell lines, and orthotopic transplantation To further evaluate the recapitulation of our GEM model to pediatric tumors in humans, we performed IHC analysis for various markers. Both pDMG models (Fig. 3 A) and pHGG models (Fig. 3 B) revealed similar characteristics to post-mortem patient samples, 1 with noticeable cellular atypia, microvascular proliferation, and pseudopalisading necrosis in de novo tumors (Fig. 3 A and B). Molecular characteristics of pDMG were present in both GEM models, with a cellular invasion of adjacent parenchyma, Ki67 positivity, Olig-2 expression, the presence of CD11b + cells, low number of CD3 + cell, and heterogeneous IL13RA2 expression (Fig. 3 A and B). In order to develop targeted immunotherapies using these models, we generated cell lines from our de novo tumors for subsequent in vitro experiments. Brain tissue from tumor-bearing animals was processed in a single-cell suspension as described in the Material and Methods, placed into culture, and maintained as neurospheres. The expression of PDGFB and IL13RA2 was confirmed by both midline and cortical tumors by FSC analysis (Fig. 3 C). To assess tumorigenicity, we orthotopically implanted these cell lines into the midline or right cortex of 4–5 days-old Nestin-tva p53 fl/fl mice. Survival analysis displayed a median survival of 42 and 41 days for midline and cortical tumor-bearing, respectively (Fig. 3 D). IHC analysis of these tumors displayed histological features similar to those of de novo tumors, with heterogeneous IL13RA2 expression, Olig-2 expression, infiltration of CD11b + cells, and a small number of CD3 + cells along with Ki67- positivity (Suppl. Figure 1A). The genomic landscape of pHGG is characterized by recurrent mutations in TP53, PTEN, and histone H3 variant H3.3 (H3F3A) 29 , 30 . In addition to Nestin-tva p53 fl/fl mice, we induced PTEN deletion into tumors using Nestin-tva p53 fl/fl PTEN fl/fl mice and introduced the H3.3K27M mutation. Immunohistological evaluation of PTEN expression in both models confirmed deletion of PTEN in p53 fl/fl PTEN fl/fl , but not p53 fl/fl mice (Fig. 3 E). Similarly, staining with an antibody detecting H3K27me3 revealed absence of staining in tumors with H3.3K27M mutation, with an exception for cells of tumor microenvironment or surrounding brain. Dual deletion of PTEN and p53 and dual deletion of PTEN and p53 with H3.3K27M generated significantly more aggressive tumors compared to p53 alone, with a median survival of mice of 31.0, 35.0, and 52.5 days in p53 fl/fl PTEN fl/fl and p53 fl/fl , respectively (Fig. 3 F). No difference in survival was seen upon introduction of the H3.3K27M compared to PTEN and p53 dual deletion (Fig. 3 F). Response of de novo tumors to CAR T- cell therapy . To investigate the suitability of our GEM model of pHGG to targeted therapy, we generated murine IL13RA2-CAR T-cells, as described previously. 22 The neurospheres of glioma cells established from cortical (Suppl. Figure 1B, C, D, and E) and midline tumors (Suppl. Figure 1F, G, H, and I) were labeled with CFSE, co-cultured with control non-transduced (NT) or CAR T-cells (CAR), and then characterized via flow cytometric analysis (gating strategy Suppl. Figure 2A and B). Both models demonstrated a significant response to CAR T-cells (Suppl. Figure 1C, Suppl. Figure 1G), with target-dependent activation of CD8+ (Suppl. Figure 1D, Suppl. Figure 1H) and CD4+ (Suppl. Figure 1E, Suppl. Figure 1I) CAR T-cells as judged by expression of CD25 and CD69 markers. Following confirmation of functionality, we tested the response to targeted therapy in vivo by treating cortical tumor-bearing mice with CAR T-cell therapy. Intracranial delivery of CAR T-cells significantly improved the survival (MS: 46 days) compared to both saline (MS: 28 days), and NT-treated animals (MS: 31 days) (Wald p-value < 0.001) (Fig. 4 A). Furthermore, 25% of mice (3 out of 12) treated with CAR T-cells survived long-term (LTS) (Fig. 4 A), and histological analysis confirmed absence of tumor in these mice (Fig. 4 B). To understand how targeted therapy effects TME cellular composition, we again treated cortical tumor-bearing mice (Suppl Fig. 1A) with CAR T cell therapy, harvested and processed the brains of CAR T-cell (CAR), non-transduced T-cell (NT), and saline treated animals into single cell suspensions, and performed multicolor flow cytometric analyses (gating strategy Suppl. Figure 2C). We observed significantly increased frequency of monocytic MDSC (M-MDSC; CD45 + CD11b + Ly6C + Ly6G lo ) (Fig. 4 C) and frequency of CD8 T-cells (Fig. 4 D), but not CD4 (Fig. 4 E), in the brains of CAR T cell treated animals comapred to saline. We observed no change in the frequency in T regulatory cells (CD45 + CD4 + FOXP3 + ) (Fig. 4 F). Furthermore, we also observed increased frequency of activated (CD45 + CD8 + CD44 + CD69 + ) (Fig. 4 G) and cytotoxic (CD45 + CD8 + GZMB + ) (Fig. 4 H) CD8 T-cells in CAR treated animals compared to saline. Together, these experiments indicate that de novo established aggressive glioma tumors expressing IL13RA2 are responsive to CAR T-cell therapy, and thus, are suitable for investigating responses and resistance of aggressive pediatric diffuse gliomas to targeted therapeutics in mice with fully competent immune system. DISCUSSION Amongst many factors, the efficacy of targeted immunotherapy depends on the targeted antigen's validity. IL13RA2 is an attractive TAA present in several CNS tumors and has been validated as an immunotherapeutic target in adult GBM 31 , 32 . To better understand IL13RA2 as a potential immunotherapeutic target in the context of pHGG, we first characterized its expression in datasets of patient tissue samples. We found that IL13RA2 is expressed at higher levels in pHGG, notably with around 45% of DIPG samples expressing IL13RA2, an observation in agreement with other reports 8 , 13 . These preliminary results suggest that IL13RA2 has the potential to be used as an immunotherapeutic target for pDMG and pHGG. A significant obstacle to developing targeted immunotherapy for pDMG and pHGG is the lack of an immunocompetent model expressing human antigens. We used the RCAS-Tva system to overcome this limitation and induce de novo tumorigenesis in immunocompetent mice. In doing so, we successfully generated pDMG and pHGG that express IL13RA2, and the addition of IL13RA2 to PDGFB-driven gliomas did not significantly impact the survival compared to the previously described PDGFB-driven tumor model of pediatric diffuse midline glioma 33 . Moreover, de novo tumors with a dual p53/PTEN deletion acquired a more aggressive phenotype than tumors with p53 deletion alone. Finally, our generated tumors recapitulated the histological and molecular hallmarks seen in patient samples, such as cellular atypia, microvascular proliferation, pseudo palisading necrosis, and invasion into surrounding brain tissue. Tumor-derived cell lines derived express IL13RA2 and reliably developed tumors when implanted orthotopically in the murine brain. Consistent with human pDMG and pHGG 34 , 35 , 25 , both de novo and orthotopically generated tumors displayed a heterogeneous expression of IL13RA2 with limited infiltration CD3 T-cells and a moderate CD11b myeloid cells in the TME. Our analysis of tumor-infiltrating T-cells and myeloid cells following CAR T-cell therapy revealed increased frequency of CD8 T-cells and monocytic MDSCs (M-MDSCs). M-MDSCs are normally recruited to sites of inflammation to help modulate immune responses and prevent excessive tissue damage. Once there, they can actively suppress T-cell response by expressing high levels of immunosuppressive molecules such as ARG1 and iNOS. Given the increased presence of tumor-infiltrating activated/cytotoxic CD8 T-cells following CAR T-cell treatment, a role of M-MDSC in supporting or dampening the tumor responses to CAR T-cells needs to be further investigated. Future studies employing single-cell RNA sequencing and multiplex immunofluorescence to characterize the TME will help to understand the changes taking place upon the introduction of immunotherapy and how these changes play a role in immunotherapeutic efficacy. Multiple recurrent mutations characterize the genomic landscape of pHGG. TP53 mutations, affecting the well-studied tumor suppressor protein p53, occur in over 40% of patients 36 . PTEN mutations are present in 10–20% of pHGG cases 29 , 30 . The most common mutation is in H3F3A, the gene encoding histone H3 variant H3.3. This mutation involves a lysine-to-methionine substitution at position 27 (H3.3K27M) and occurs in 70–80% of cases 36 , 37 . Furthermore, a strong positive correlation between IL13RA2 expression and H3.3K27M mutation has been found in pHGG and pDMG 32 , 38 . In this study, we successfully used the RCAS-Tva model to generate H3.3K27M mutant tumors lacking p53 and PTEN that express IL13RA2. Furthermore, we demonstrate that de novo IL13RA2-expressing tumors respond to CAR T-cell therapy, with some animals surviving long term. The strength of the GEM model is its versatility in incorporating molecular alterations, and this work serves as a proof of concept that relevant human antigens can be readily incorporated into GEM models and may serve as useful preclinical tools. Clinical studies using dual and multispecific targeting approaches have emerged in recent years. There is currently one clinical study using B7-H3-IL13RA2-CAR T cells in pediatric diffuse gliomas (NCT06221553); Another clinical study featuring a quad-specific B7H3-HER2-EGFR-IL13RA2 CAR T-cell in pediatric diffuse gliomas (NCT05768880). By incorporating additional human tumor-associated antigens (e.g., B7-H3, EGFRvIII, GD2, and HER2), this model could strengthen multi-targeting approaches for pediatric diffuse gliomas by enabling preclinical development in an immunocompetent host. CONCLUSION We developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, IL13RA2 and demonstrated the suitability of the model for evaluation of targeted therapy such as CAR T cells. We envision that this model will permit preclinical assessment of several human antigen-targeting immunotherapeutics, including CAR-T cells, bi- or multispecific T and NK cells engaging antibodies, and antibody-drug conjugates therapies within an immunocompetent host. After establishing the potential anti-tumor effect of each of these therapies, combinatorial approaches with concurrent radiation, chemotherapy, or targeted therapies, or in conjunction with other immunotherapeutic approaches, such as checkpoint inhibitors or other antibodies, will be considered. A robust evaluation of such strategies will allow for potential clinical translation to improve the outcome for children impacted by these devastating tumors. Abbreviations ARG1 - Arginase 1 BCA - Bicinchoninic Acid CAR T-cells - Chimeric Antigen Receptor-Modified T-Cells CNS - Central Nervous System DMEM - Dulbecco’s Modified Eagle’s Medium DMG - Diffuse Midline Gliomas DIPG - Diffuse Intrinsic Pontine Glioma FBS - Fetal Bovine Serum FSC - Flow Cytometry GAPDH - Glyceraldehyde 3-Phosphate Dehydrogenase GEMM - Genetically Engineered Mouse Model GZMB - Granzyme B H3F3A - Histone H3 Variant H3.3 H&E - Hematoxylin and Eosin HSD - Honest Significant Difference IACUC - Institutional Animal Care and Use Committee IL13RA2 - Interleukin 13 Receptor Alpha 2 IHC - Immunohistochemistry iNOS - Inducible Nitric Oxide Synthase LTS - Long-Term Survival M-MDSCs – Monocytic Myeloid-Derived Supressor Cells mPER - Mammalian Protein Extraction Reagent NFDM - Non-Fat Dry Milk PBS - Phosphate-Buffered Saline PFA - Paraformaldehyde pDMG - Pediatric Diffuse Midline Gliomas pHGG - Pediatric High-Grade Glioma T:E - Target-to-Effector Declarations ETHICS DECLARATIONS Consent for publication N/A Competing interests Irina Balyasnikova is an inventor of a single-chain antibody targeting IL13RA2 and the CAR construct used in this study. All other authors declare no competing interests. Ethics approval Human tumor samples were initially obtained under Institutional Review Board approved protocol (#IRB 2019-3164) per Ann and Robert H. Lurie Children's Hospital of Chicago. All animal studies were approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC). FUNDING This study was supported in part by NINDS R01NS106379 (IVB) and R01NS122395 (IVB) grants and the Washington Square Health Foundation (MS). This study was supported in part by NINDS R01NS106379 (IVB) and R01NS122395 (IVB) grants and the Washington Square Health Foundation (MS). Histology services were provided by the Northwestern University Mouse Histology and Phenotyping Laboratory, which is supported by National Cancer Institute Grant P30-CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. In addition, this work was supported by the Northwestern University – Flow Cytometry Core Facility supported by the Cancer Center Support Grant (NCI CA060553). The Northwestern Nervous System Tumor Bank is supported by the P50CA221747 SPORE for Translational Approaches to Brain Cancer. ACKNOWLEDGEMENTS The authors thank Liliana Ilut and Quanli Liu for their technical assistance in initial stages of the project. References Mackay, A. et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell 32 , 520-537 e525 (2017). https://doi.org:10.1016/j.ccell.2017.08.017 Warren, K. E. et al. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol 14 , 326-332 (2012). https://doi.org:10.1093/neuonc/nor190 Foster, J. B. et al. Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol 21 , 1226-1238 (2019). https://doi.org:10.1093/neuonc/noz077 Berlow, N. E. et al. IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. PLoS One 13 , e0193565 (2018). https://doi.org:10.1371/journal.pone.0193565 Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 , 226-231 (2012). https://doi.org:10.1038/nature10833 Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44 , 251-253 (2012). https://doi.org:10.1038/ng.1102 Khuong-Quang, D. A. et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124 , 439-447 (2012). https://doi.org:10.1007/s00401-012-0998-0 Haydar, D. et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol 23 , 999-1011 (2021). https://doi.org:10.1093/neuonc/noaa278 Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24 , 572-579 (2018). https://doi.org:10.1038/s41591-018-0006-x Majzner, R. G. et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res 25 , 2560-2574 (2019). https://doi.org:10.1158/1078-0432.CCR-18-0432 Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med 26 , 712-719 (2020). https://doi.org:10.1038/s41591-020-0821-8 Lian, X. et al. Design considerations of an IL13Ralpha2 antibody-drug conjugate for diffuse intrinsic pontine glioma. Acta Neuropathol Commun 9 , 88 (2021). https://doi.org:10.1186/s40478-021-01184-9 Okada, H. et al. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88 , 245-250 (2008). https://doi.org:10.1007/s11060-008-9566-9 Pollack, I. F. et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 32 , 2050-2058 (2014). https://doi.org:10.1200/JCO.2013.54.0526 Brown, C. E. et al. Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med (2024). https://doi.org:10.1038/s41591-024-02875-1 Misuraca, K. L., Cordero, F. J. & Becher, O. J. Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. Front Oncol 5 , 172 (2015). https://doi.org:10.3389/fonc.2015.00172 Larson, J. D. et al. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. Cancer Cell 35 , 140-155 e147 (2019). https://doi.org:10.1016/j.ccell.2018.11.015 Holland, E. C., Hively, W. P., DePinho, R. A. & Varmus, H. E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12 , 3675-3685 (1998). https://doi.org:10.1101/gad.12.23.3675 Haag, D. et al. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. Cancer Cell 39 , 407-422 e413 (2021). https://doi.org:10.1016/j.ccell.2021.01.005 Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340 , 857-861 (2013). https://doi.org:10.1126/science.1232245 Becher, O. J. et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 70 , 2548-2557 (2010). https://doi.org:10.1158/0008-5472.CAN-09-2503 Pituch, K. C. et al. Adoptive Transfer of IL13Ralpha2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Mol Ther 26 , 986-995 (2018). https://doi.org:10.1016/j.ymthe.2018.02.001 Pituch, K. C. et al. Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proc Natl Acad Sci U S A 118 (2021). https://doi.org:10.1073/pnas.2015800118 Gump, J. M. et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun 3 , 30 (2015). https://doi.org:10.1186/s40478-015-0211-5 Ross, J. L. et al. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. Brain 144 , 53-69 (2021). https://doi.org:10.1093/brain/awaa382 Zannikou, M. et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer 11 (2023). https://doi.org:10.1136/jitc-2022-006239 Heiss, J. D. et al. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J Neurosurg Pediatr 23 , 333-342 (2018). https://doi.org:10.3171/2018.9.PEDS17225 Brown, C. E. et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med 375 , 2561-2569 (2016). https://doi.org:10.1056/NEJMoa1610497 Jones, C. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 19 , 153-161 (2017). https://doi.org:10.1093/neuonc/now101 Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 , 226-231 (2012). https://doi.org:10.1038/nature10833 Debinski, W. & Gibo, D. M. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6 , 440-449 (2000). Debinski, W., Slagle, B., Gibo, D. M., Powers, S. K. & Gillespie, G. Y. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48 , 103-111 (2000). https://doi.org:10.1023/a:1006446426611 Cordero, F. J. et al. Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG. Mol Cancer Res 15 , 1243-1254 (2017). https://doi.org:10.1158/1541-7786.MCR-16-0389 Plant, A. S. et al. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol 137 , 269-278 (2018). https://doi.org:10.1007/s11060-017-2737-9 Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol 21 , 83-94 (2019). https://doi.org:10.1093/neuonc/noy145 Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genetics 46 , 444-450 (2014). https://doi.org:10.1038/ng.2938 Khuong-Quang, D.-A. et al. K27M mutation in histone H3. 3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta neuropathologica 124 , 439-447 (2012). Deng, H. et al. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma. Molecular Cancer Research 16 , 623-633 (2018). https://doi.org:10.1158/1541-7786.mcr-17-0460 Additional Declarations Competing interest reported. Irina Balyasnikova is an inventor of a single-chain antibody targeting IL13RA2 and the CAR construct used in this study Supplementary Files Seblaniatal.SUPPLEMENTALMATERIALS.docx SeblaniWESTERNORIGINALBLOTS.pdf Cite Share Download PDF Status: Published Journal Publication published 02 Apr, 2025 Read the published version in Acta Neuropathologica Communications → Version 1 posted Editorial decision: Revision requested 27 Dec, 2024 Reviews received at journal 11 Dec, 2024 Reviewers agreed at journal 25 Nov, 2024 Reviewers invited by journal 20 Nov, 2024 Editor assigned by journal 13 Nov, 2024 Submission checks completed at journal 13 Nov, 2024 First submitted to journal 05 Nov, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5398280","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":382139410,"identity":"396e26c2-ffec-48e7-94c0-ad715ee22df5","order_by":0,"name":"Maggie Seblani","email":"","orcid":"","institution":"Lurie Children's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Maggie","middleName":"","lastName":"Seblani","suffix":""},{"id":382139411,"identity":"1e50c949-6f03-4774-8c44-59b2a51d5488","order_by":1,"name":"Markella Zannikou","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Markella","middleName":"","lastName":"Zannikou","suffix":""},{"id":382139412,"identity":"1459c70e-845a-4a49-9524-e16d7df07f1d","order_by":2,"name":"Joseph Duffy","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Joseph","middleName":"","lastName":"Duffy","suffix":""},{"id":382139413,"identity":"a025295a-ad99-4aa5-9a8c-c305d3096a55","order_by":3,"name":"Rebecca Levine","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Rebecca","middleName":"","lastName":"Levine","suffix":""},{"id":382139414,"identity":"97cc1e86-9fd2-48ab-9533-25e13c92f97c","order_by":4,"name":"Aditi Thakur","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Aditi","middleName":"","lastName":"Thakur","suffix":""},{"id":382139415,"identity":"d9de0f19-929d-4f2d-bce4-8dbb234f728c","order_by":5,"name":"Montserrat Puigdelloses- Vallcorba","email":"","orcid":"","institution":"Icahn School of Medicine at Mount Sinai","correspondingAuthor":false,"prefix":"","firstName":"Montserrat","middleName":"Puigdelloses-","lastName":"Vallcorba","suffix":""},{"id":382139416,"identity":"3f5a101d-04f3-4717-88c6-1081aa2e642e","order_by":6,"name":"Crag Horbinski","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Crag","middleName":"","lastName":"Horbinski","suffix":""},{"id":382139417,"identity":"e8e925d1-7f6a-494c-9f45-92a15d7bfd73","order_by":7,"name":"Jason Miska","email":"","orcid":"","institution":"Northwestern University","correspondingAuthor":false,"prefix":"","firstName":"Jason","middleName":"","lastName":"Miska","suffix":""},{"id":382139418,"identity":"8e80c298-1c8b-44b6-82b2-27aeafa508a4","order_by":8,"name":"Dolores Hambardzumyan","email":"","orcid":"","institution":"Icahn School of Medicine at Mount Sinai","correspondingAuthor":false,"prefix":"","firstName":"Dolores","middleName":"","lastName":"Hambardzumyan","suffix":""},{"id":382139419,"identity":"b5f530ab-a6d3-483a-bf59-6d77fd9f0e8f","order_by":9,"name":"Oren Becher","email":"","orcid":"","institution":"Icahn School of Medicine at Mount Sinai","correspondingAuthor":false,"prefix":"","firstName":"Oren","middleName":"","lastName":"Becher","suffix":""},{"id":382139420,"identity":"42f642c6-25c6-4281-a1aa-754e02621684","order_by":10,"name":"Irina Balyasnikova","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+0lEQVRIiWNgGAWjYBACNgbGBhCS4QfxgAw4QGZj1cIjCVJxsAEshF8LTJbH4ACxWvikD7c9+LnDjsf4dvOxzx93HJaTnw9kFDDYyG44gMNhfInthr1nknnM7hxLnnHwzGFjg2NsybNnMKQZ49TCw9gmwdvGzGN2I8eY4WDb7cQNbDzGzDwMhxPxaZH821bPYzwDoqV+fhv/Z6CW/3i1SPO2HeYxkIBoSWA4xsMM1HIAvxbZM8d5JG6kJTOcbftvuOFYGtBhBsnGM3Foke9hfyb5dke1HP+M5MMMlW1p8vLNhx8z81TYyfbh0IILGJCmfBSMglEwCkYBKgAAq5VZ27wOBZwAAAAASUVORK5CYII=","orcid":"","institution":"Northwestern University","correspondingAuthor":true,"prefix":"","firstName":"Irina","middleName":"","lastName":"Balyasnikova","suffix":""}],"badges":[],"createdAt":"2024-11-05 22:53:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5398280/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5398280/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s40478-025-01991-4","type":"published","date":"2025-04-02T15:57:10+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":71170164,"identity":"7e424b3e-6ab2-432b-880f-4ef97676a1eb","added_by":"auto","created_at":"2024-12-11 19:12:20","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1030374,"visible":true,"origin":"","legend":"\u003cp\u003eIL13RA2 shows heterogenous expression in human DIPG. (A) IL13RA2 gene expression in pediatric brain tumors from Gump database was analyzed using GlioVis (http://gliovis.bioinfo.cnio.es/). Tukey's Honest Significant Difference (HSD) was performed to compare IL13RA2 gene expression between pediatric tumors. Significance was denoted in the graph by one asterisk (*) where p\u0026lt;0.05, two (**) where p\u0026lt;0.01, and three (***) where p\u0026lt;0.001. (B) IL13RA2 histopathological scores of post-mortem patient samples. (C) Representative images of each IL13RA2 histopathological score in post-mortem human pDMG patient samples (top panel) and corresponding H\u0026amp;E stains (bottom panel). Each image includes high-power insets at low-power fields (top right hovering image)\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/f04f618e792768a2ca91016b.png"},{"id":71170165,"identity":"f2201b15-5c15-460a-ab19-15dcebd53e00","added_by":"auto","created_at":"2024-12-11 19:12:20","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":432868,"visible":true,"origin":"","legend":"\u003cp\u003e(A) Visual schematic of RCAS vector generated with PDGFB and IL13RA2 transgenes flanked by recombination att sites used to transfect DF-1 cells. Validation of PDGFB and IL13RA2 expression in DF-1 by (B) flow cytometry and (C) western blot. (D) Comparison of survival for Nestin-Tva;p53\u003csup\u003efl/fl\u003c/sup\u003e mice injected at midline location with DF-1 producing virus containing RCAS-CRE and PDGFB or PDGFB+IL13RA2.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003e\u003cstrong\u003eAnalysis of GEM models of midline glioma expressing IL13RA2.\u003c/strong\u003e\u003c/u\u003e\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/f6b87e0df2de2a57ed079c9e.png"},{"id":71170162,"identity":"9963c144-9288-4300-9c15-b846d7c86683","added_by":"auto","created_at":"2024-12-11 19:12:19","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":971108,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003e\u003cstrong\u003eHistopathological analysis of \u003c/strong\u003e\u003c/u\u003e\u003cu\u003e\u003cem\u003e\u003cstrong\u003ede novo\u003c/strong\u003e\u003c/em\u003e\u003c/u\u003e\u003cu\u003e\u003cstrong\u003e tumors.\u003c/strong\u003e\u003c/u\u003e \u003cem\u003eDe novo\u003c/em\u003e tumor generation for (A) diffuse midline glioma through midline injection, 49 days post-injection, and (B) supratentorial high-grade glioma through cortical injection, 50 days post-injection. (A-B) Whole brain tissue section and tumor stained with H\u0026amp;E. Higher magnification of inset images reveal (i) infiltrative tumor cells, (ii, arrows) microvascular proliferation, and (iii, asterisk) pseudo-palisading necrosis. (C). Flow cytometric analysis of IL13RA2 and PDGFB expression in cell lines generated from the midline and cortical \u003cem\u003ede novo\u003c/em\u003e tumors. (D) Survival analysis of orthotopically injected cell lines in the midline and cortical location of Nestin-Tva; p53\u003csup\u003efl/fl\u003c/sup\u003e mice. (E) Histological validation of PTEN expression, PTEN loss, and H3K27me3 loss in \u003cem\u003ede novo\u003c/em\u003e tumors derived from p53\u003csup\u003efl/fl\u003c/sup\u003e/PTEN\u003csup\u003ewt/wt\u003c/sup\u003e, p53\u003csup\u003efl/fl\u003c/sup\u003e/PTEN\u003csup\u003efl/fl\u003c/sup\u003e, and p53\u003csup\u003efl/fl\u003c/sup\u003ePTEN\u003csup\u003efl/fl\u003c/sup\u003eH3.3K27M\u003csup\u003emut\u003c/sup\u003e mice, respectively. (F) Suvival comparison between p53\u003csup\u003efl/fl\u003c/sup\u003e, p53\u003csup\u003efl/fl\u003c/sup\u003ePTEN\u003csup\u003efl/fl\u003c/sup\u003e, and p53\u003csup\u003efl/fl\u003c/sup\u003ePTEN\u003csup\u003efl/fl\u003c/sup\u003eH3.3K27M\u003csup\u003emut\u003c/sup\u003e mouse models.\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/e6e7078ee7f0cedf4cf9fe2c.png"},{"id":71170538,"identity":"b85c6ac3-3883-452b-8bab-62de8bbfa74f","added_by":"auto","created_at":"2024-12-11 19:20:20","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":2391299,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003e\u003cem\u003e\u003cstrong\u003eDe novo\u003c/strong\u003e\u003c/em\u003e\u003c/u\u003e\u003cu\u003e\u003cstrong\u003e PDGF-B/ IL13RA2 overexpressing tumors respond to CAR T-cell therapy\u003c/strong\u003e\u003c/u\u003e. (A) Survival analysis of mice with \u003cem\u003ede novo\u003c/em\u003e cortical tumor of Nestin-Tva; p53\u003csup\u003efl/fl\u003c/sup\u003e/ PTEN\u003csup\u003e fl/fl\u003c/sup\u003e mice treated with saline (n=8), non-transduced (NT) T-cells (n=13) or CAR T-cells (n=12), ***p\u0026lt;0.0001. (B) H\u0026amp;E stain of mouse brain from control (left panel) and CAR T-cell-treated (right panel) long-term surviving mice. (C-H) Flow cytometric analysis of tumor microenvironment of nestin-Tva; p53\u003csup\u003efl/fl\u003c/sup\u003e/ PTEN\u003csup\u003e fl/fl\u003c/sup\u003e mice treated with saline (white), non-transduced (NT) T-cells (blue) or CAR T-cells (red).\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/12bf7ecf5098aaf52365137a.png"},{"id":80082789,"identity":"bc054ba2-35e9-442c-9ea3-81f7ab99439e","added_by":"auto","created_at":"2025-04-07 16:09:24","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5367556,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/e9a692fd-5793-4e58-b820-61211296418a.pdf"},{"id":71170167,"identity":"3e75581c-6840-49d1-a65e-d8a370778fe6","added_by":"auto","created_at":"2024-12-11 19:12:20","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":6729376,"visible":true,"origin":"","legend":"","description":"","filename":"Seblaniatal.SUPPLEMENTALMATERIALS.docx","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/63f0dd30b2cad22bf7a3b1bc.docx"},{"id":71170166,"identity":"1c974437-be20-4d6c-a06f-95dfc7644a7e","added_by":"auto","created_at":"2024-12-11 19:12:20","extension":"pdf","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":16925736,"visible":true,"origin":"","legend":"","description":"","filename":"SeblaniWESTERNORIGINALBLOTS.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5398280/v1/b55f8d6af9c4fe700f6f08f5.pdf"}],"financialInterests":"Competing interest reported. Irina Balyasnikova is an inventor of a single-chain antibody targeting IL13RA2 and the CAR construct used in this study","formattedTitle":"\u003cp\u003eIL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eAmong pediatric cancers, diffuse midline gliomas (DMG) are notorious for their universally poor outcomes\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. The prototypical diffuse midline glioma, diffuse intrinsic pontine glioma (DIPG), is an aggressive tumor that has a median survival of less than one year from diagnosis and is currently incurable\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Radiation provides limited symptom control and extends overall survival on average by only three months. The lack of sustained response to conventional therapies reinforces the pressing need for new therapies.\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThe recent success of cancer immunotherapy in adults and children with hematologic malignancies has intensified efforts to develop immunomodulatory applications in central nervous system (CNS) tumors. Advances in molecular characterization of midline gliomas via increased tissue sampling at diagnosis and post-mortem have enabled the subgrouping of tumors and identified molecular drivers\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan additionalcitationids=\"CR6\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Surface markers, such as GD2 and B7-H3, have previously been characterized based on expression levels and degree of inter- and intra-patient heterogeneity\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Preclinical studies of chimeric antigen receptor-modified T-cells (CAR T-cells) targeting GD2 and B7-H3 (CD276) have translated into clinical trials (NCT04196413, NCT04099797, NCT04185038)\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Interleukin-13 receptor alpha 2 (IL13RA2) is another attractive immunotherapeutic target in pediatric HGG (pHGG). High expression of IL13RA2 has been described in DIPG and other pHGG tissues\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Within adult-type diffuse gliomas, IL13RA2 targeting therapies have been the focus of multiple preclinical and clinical studies. One study utilized the IL13RA2 epitope for a glioma vaccine\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e, and a phase I clinical trial featuring IL13RA2 targeting CAR T-cells in IL13RA2-positive glioblastoma in adults has been recently completed\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Autologous CAR T-cells targeting IL13RA2 in patients with recurrent or refractory pHGG are currently being evaluated (NCT04510051). Overall, the advancements in molecular characterization, cellular engineering capabilities, and the growing number of clinical trials justify the investigation of targeted immunotherapy for DMG.\u003c/p\u003e \u003cp\u003eOrthotopic implantation of murine glioma cell lines into immunocompetent hosts is predominantly used for preclinical evaluation of targeted immunotherapies. However, the inability of these models to recapitulate the tumor microenvironment and failure to express targetable human antigens remains a limitation for clinical translation. Therefore, developing an immunocompetent preclinical model which both recapitulates DMG and expresses targetable human antigens is paramount. Although these advances provide a growing number of targets for immunotherapy and justify further investigation into IL13RA2 as a target, the lack of an immunocompetent preclinical model of DIPG that expresses human IL13RA2 hinders the development of IL13RA2-directed immunotherapies.\u003c/p\u003e \u003cp\u003eA genetically engineered mouse model (GEMM) is one such system that permits tumorigenesis in the presence of a competent immune system\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. GEMMs enable the spatiotemporal introduction of specific genetic abnormalities and permit the investigation of various stages of tumor development, including tumor initiation\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. The RCAS/Tva system is a powerful genetic engineering tool that enables specific somatic cell gene transfer into cells engineered to express the Tva receptor\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Holland and colleagues previously developed GEMM, which uses the RCAS/Tva system to delete p53 in Tva-positive cells and induce gliomagenesis\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Using engineered mice with Tva receptors in nestin-positive progenitor cells, a candidate cell of origin for DIPG\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, Becher and colleagues expanded this model to induce brainstem gliomogenesis in newborn mice\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. The strength of this model is in its versatility, as it enables customization to express exogenous human genes of interest, namely immunotherapeutic targets, within Tva-expressing cells.\u003c/p\u003e \u003cp\u003eWe have previously developed an IL13RA2-specific antibody and incorporated it into CAR T-cells and bi-specific T-cell engagers for preclinical evaluation in adult glioblastoma\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Here, we integrated IL13RA2 into a construct encoding for PDGFB and used the RCAS/Tva system to develop a novel immunocompetent GEMM that both recapitulates diffuse midline gliomas and expresses the human glioma-associated antigen IL13RA2. We tested the feasibility of this model to assess the anti-tumor efficacy of our IL13RA2-CAR T-cells. Engineering diffuse midline and hemispheric high-grade gliomas that express IL13RA2 will fill a significant gap in existing models and allow preclinical mechanistic and therapeutic studies in corresponding pediatric brain tumors.\u003c/p\u003e"},{"header":"MATERIALS and METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eAnalysis of TCGA patient data sets\u003c/h2\u003e \u003cp\u003eLevels of IL13RA2 gene expression in pediatric brain tumors were assessed using a publicly available microarray expression profile Gump database (tumor samples: 106, non-tumor: 6; GEO ID: GSE68015). RNA-seq data from Gump were visualized using GlioVis (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://gliovis.bioinfo.cnio.es/\u003c/span\u003e\u003cspan address=\"http://gliovis.bioinfo.cnio.es/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e), with the relative expression of IL13RA2 determined from log2 transformation of normalized count reads.\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e Statistical significance between pediatric tumors was determined using Tukey's Honest Significant Difference (HSD) within GlioVis, with one asterisk (*) where p\u0026thinsp;\u0026lt;\u0026thinsp;0.05, two (**) where p\u0026thinsp;\u0026lt;\u0026thinsp;0.01, and three (***) where p\u0026thinsp;\u0026lt;\u0026thinsp;0.001.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eHistology and immunohistochemistry of human samples\u003c/h2\u003e \u003cp\u003eHuman tumor samples were initially obtained under Institutional Review Board approved protocol (#IRB 2019\u0026ndash;3164) per Ann and Robert H. Lurie Children's Hospital of Chicago. All samples were de-identified. Tissue sections were stained with H\u0026amp;E and for IL13RA2 (R\u0026amp;D antibody, cat AF146) IHC. Scoring was performed independently by a neuropathologist (C.H.). Scores were established on the percent positively labeled tumor cells; 0 is no positivity, 1 is \u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e\u0026le;\u003c/span\u003e\u0026thinsp;10% positive tumor cells, 2 is 10\u0026ndash;50% positive tumor cells, 3 is \u0026ge;\u0026thinsp;50% positive tumor cells. PTEN immunohistochemistry staining was performed on a Leica Bond Rx platform (Leica). Primary anti-PTEN antibodies were diluted 1:100 (Cell Signaling, #9559). Anti-rabbit secondary antibodies were purchased from Leica. Digital slide images were acquired using a Nanozoomer 2.0HT whole-slide scanner (Hamamatsu Photonic K.K.) and observed offline with NDP.view2 software (Hamamatsu).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eCell lines and cell culture reagents\u003c/h2\u003e \u003cp\u003eDF-1 (chicken fibroblast) cell line was obtained from ATCC (cat #CRL-12203). All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Manassas, Virginia; Cat #30-2002) supplemented with 10% fetal bovine serum (FBS) (R\u0026amp;D Systems, Minneapolis, MN), 1% penicillin/streptomycin (P/S) (Corning, Corning, NY; Cat #30-002-CI) and 2mM L-glutamine (Corning, Corning, NY; Cat # 25-005-CI). Dulbecco's Phosphate-buffered saline (PBS) was obtained from Thermo Fisher. GeneJuice was purchased from (Millipore Sigma).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eCloning IL13RA2 in vector encoding for PDGFB cDNA\u003c/h2\u003e \u003cp\u003eThe cDNA encoding T2A-IL13RA2 was synthesized by GenScript, subcloned into the RCAS-PDGFB-HA vector\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e following the PDGFB cDNA using CloneEZ method, and verified by Sanger sequencing (GenScript, Piscataway, NJ). The plasmid was amplified in DH5a cells (NewEngland Biolabs, Ipswich, MA; Cat #C2987H) and purified using a plasmid purification midi-kit (Qiagen, Hilden, Germany; Cat # 12145).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of DF-1 cells producing virus encoding for PDGFB, RCAS-Cre, and PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2\u003c/h2\u003e \u003cp\u003eOur approach expands upon a previously described use of the RCAS-Tva system for GEMM creation.\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e Briefly, we cultured DF-1 cells in optimal growth conditions in DMEM supplemented with 10% FBS, 1% P/S, and 2 mM L-glutamine. Cells were transfected with RCAS plasmids (RCAS-Cre, PDGFB, and PDGFB\u0026thinsp;+\u0026thinsp;IL13Rα) using GeneJuice (Millipore Sigma, Burlington, MA; Cat # 70967), per the manufacturer's protocol. To propagate the necessary cell number and adequate retrovirus for intracranial injection, we serially passaged the three transfected cell groups upon reaching 80\u0026ndash;90% density for up to five passages.\u003c/p\u003e \u003cp\u003e \u003cem\u003eGeneration of CAR T-cells for targeting of IL13RA2-expressing de novo tumors.\u003c/em\u003e \u003c/p\u003e \u003cp\u003eMurine CAR T-cells targeting IL13RA2 were generated as we previously reported\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. CAR T-cells were tested for their ability to kill newly generated cell lines in co-culture with newly generated IL13RA2-expressing glioma lines for 48 hours at 1:20 target-to-effector (T:E) ratio.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eWestern blot\u003c/h2\u003e \u003cp\u003eCells were cultured in complete DMEM as previously described. Cells were collected, pelleted, and then resuspended into one mL of cold Dulbecco's Phosphate-buffered saline (PBS) (4\u0026deg;C). Cells were counted via the trypan-blue exclusion method, pelleted by centrifugation (400x g, 5 min), and lysed in ice-cold Mammalian Protein Extraction Reagent (mPER) (Thermo Scientific, Waltham, MC) at a concentration of 20,000 cells/\u0026micro;L mPER. Protein concentration was measured using a Pierce\u003csup\u003e\u0026trade;\u003c/sup\u003e bicinchoninic acid (BCA) protein assay kit (Thermo Scientific. Protein samples were then prepared in Laemmli Sample Buffer (Bio-Rad, Hercules, CA; Cat #1610747) with 2.5% 2-Mercaptoethanol (Sigma Aldrich, St. Louis, MO; Cat #M6250) and denatured at 95\u0026deg;C for 5 min. Protein samples and 250 kDa Precision Plus Protein standard (Bio-Rad Laboratories, Hercules, CA) were loaded into each well of a 4\u0026ndash;20% Midi-PROTEAN\u0026reg; TGX Stain-Free\u0026trade; gel (Bio-Rad). Proteins were separated by size using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a methanol-activated 0.2 \u0026micro;m PVDF membrane (Millipore Sigma, Burlington, MA; Cat #IPVH08100) using the Trans-Blot\u0026reg; Turbo Transfer System\u0026trade; (Bio-Rad). Membranes were blocked with 5% non-fat dry milk (NFDM) in tris-buffered saline plus 0.1% Tween-20 (TBST) (Boston Bioproducts, Ashland, MA; Cat #IBB180) for 2 hours at RT. Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R\u0026amp;D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4\u0026deg;C. The next day, membranes were washed with TBST and incubated with anti-rabbit HRP-linked Secondary Antibody (1:1000) (Cell Signaling Technology, 7074) for GAPDH and anti-HA tag and chicken anti-goat Secondary Antibody (Santa Cruz Biotechnology, sc-2953) for IL13RA2. Blots were washed with TBST, incubated with Clarity\u0026trade; Western ECL Substrate (Bio-Rad), and detected via chemiluminescent image acquired by ChemiDoc\u0026trade; MP Imaging System (Bio-Rad).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eFlow Cytometry\u003c/h2\u003e \u003cp\u003eCells were maintained in culture with complete DMEM. Cells were collected, pelleted, and incubated with TruStain Fc Blocking Antibody (1:200 in 1% FBS in DPBS) (4\u0026deg;C). Next, 100,000 cells were added to each tissue culture-treated V-bottom plate well. Cells were pelleted and stained on ice with PE anti-human IL13RA2 (Biolegend, 354403). Live cells were labeled with a fixable viability stain (Invitrogen, 65-0865-14). Cells were then fixed, permeabilized, and stained with Alexa-Fluor 488 Anti-HA antibody (Biolegend, 901509) to detect PDGFB. Antibodies against CD45, CD4, CD8, CD69, CD25, Granzyme B, CD44, FoxP3, CD11b, Ly6C and Ly6G (BioLegend) were used for analysis of T-cell activation and myeloid cell presence in tumors environment in response to CAR T-cell treatment. Data acquisition was done using the FACSymphony A5-Laser Analyzer, BD.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eHistology and immunohistochemistry of mouse samples\u003c/h2\u003e \u003cp\u003eAt selected time points or based upon clinical deterioration, animals were perfused with PBS to collect brain tissue for sectioning. Tissue was fixed in 4% paraformaldehyde (PFA), then paraffin-embedded, cut into 4-micron sections, and stained with hematoxylin and eosin (H\u0026amp;E). Further immunohistochemistry staining was obtained using following antibodies: IL13RA2 (R\u0026amp;D AF146; 1:200), Olig2 (Abcam ab109186; 1:2000), Ki67 (Abcam ab16667; 1:500), CD3 (Abcam ab16669; 1:1000), CD11b (Abcam ab133357; 1:3000). To demonstrate the PTEN and H3K27me3 absence in glioma cells, the staining of tissues was carried out using PTEN (138G6) and Tri-Methyl-Histone H3 (Lys27) rabbit (C36B11, 1:300) antibodies recognizing wild-type PTEN and H3.3 histon proteins (Cell Signaling).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eAnimal Studies\u003c/h2\u003e \u003cp\u003eNestin-tva (Ntv-a) p53\u003csup\u003efl/fl\u003c/sup\u003e or Ntv-a p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN \u003csup\u003efl/fl\u003c/sup\u003e (obtained from Dr. Becher Laboratory) mice were bred in-house per animal protocols approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC). Our study included male and female mice with no effect of sex as a biological variable being evaluated explicitly in the study. Suspensions of virus-producing cells were injected into the hindbrain of Ntv-a p53\u003csup\u003efl/fl\u003c/sup\u003e mice pups between three to five post-natal days of age, using cryoanesthesia during the procedure. We evaluated two experimental groups: 1) RCAS-PDGFB and 2) RCAS-PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2 with p53 or p53/PTEN loss, with the former as the established model and the latter our new model with a combined cell count of 1-2x10\u003csup\u003e5\u003c/sup\u003e cells/mL per pup (a 1:1 ratio of RCAS-Cre with PDGFB or PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2) suspended in PBS for a total volume of 1.2 \u0026micro;L. In a separate experiment, cells producing RCAS-H3.3 K27M were added to Ntv-a p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN \u003csup\u003efl/fl\u003c/sup\u003e model. To generate DIPG-bearing mice, the injection site was approximately 2 mm posterior to the bregma along the midline using a Hamilton syringe and custom needle. Hemispheric tumors were induced by injecting pups about 1 mm posterior to the bregma and 1 mm right of the midline. Upon postprocedural recovery and rewarming, the pups were returned to their nursing mother. Following injection, mice were monitored closely for symptoms consistent with tumor involvement, including ataxia, seizures, enlarged head, and weight loss. For assessment with CAR T-cell therapy, mice bearing \u003cem\u003ede novo\u003c/em\u003e cortical tumors were injected with 1 x10\u003csup\u003e6\u003c/sup\u003e of non-transduced control or CAR T-cells in the same coordinates as an original tumor initiation site approximately two weeks after tumor induction. Brains were collected 72 hours post CAR T-cells injection for flow cytometric analysis of infiltrating immune cells. Survival outcomes were monitored, and mice were designated as long-term survivors (LTS) if they demonstrated no signs of disease at a 120-day post-injection interval. Brains of LTS mice were collected and histologically evaluated to confirm tumor absence.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of cell lines for orthotopic model\u003c/h2\u003e \u003cp\u003eCell lines were generated by processing tumor-bearing tissue obtained from symptomatic mice. Mice were anesthetized with a solution consisting of 200 mg/kg ketamine and 20 mg/kg xylazine and perfused with PBS before neoplastic tissue was processed with the NeuroCult\u003csup\u003e\u0026trade;\u003c/sup\u003e enzymatic dissociation Kit (StemCell Technologies, 05715) per manufacturer's instructions. Cells were maintained as neurospheres in NeuroCult\u003csup\u003e\u0026trade;\u003c/sup\u003e proliferation media (Stem Cell Technologies, Vancouver, Canada; Cat #05072) with the addition of mouse cell proliferation supplement (Stem Cell Technologies, Cat #05701), P/S, heparin at 2\u0026micro;g/mL and 10ng/mL epidermal growth factor, and 20ng/mL basic fibroblast growth factor. For orthotopic experiments, mouse pups were injected with 1 x 10\u003csup\u003e5\u003c/sup\u003e cells (1.2 \u0026micro;L) per animal in the hindbrain and the right cortex, as described in animal studies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStatistics\u003c/h2\u003e \u003cp\u003eStatistical data analyses were executed using GraphPad 8 (Prism, La Jolla, CA) and Microsoft Excel. Significance was defined as \u003cem\u003ep\u003c/em\u003e less than 0.05 in all statistical tests. P values were established as follows: *\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;.05, **\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;.01, *** \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;.001, and **** \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;.0001. As indicated, data in two groups were analyzed for statistical significance using the unpaired Mann-Whitney test or an unpaired two-tailed Student's t-test. One- or two-way ANOVA was used for multiple groups, followed by Tukey's or Dunnett's multiple comparisons test. Animal survival analysis was performed by generating Kaplan-Meier plots using the Wald test to determine the p-value.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eAnalysis of IL13RA2 expression in patient tissues\u003c/h2\u003e \u003cp\u003eIL13RA2 expression in adult-type diffuse high-grade gliomas is well established, and it has been used as an immunotherapeutic target in multiple preclinical and clinical studies.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e,\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e To determine the relative expression in pediatric CNS tumors, we used GlioVis to visualize IL13RA2 gene expression within the publicly available Gump database (GEO ID: GSE68015). Increased IL13RA2 mRNA expression was found in pediatric-type diffuse high-grade gliomas (pHGG) compared to non-neoplastic brain tissue and other pediatric brain tumors (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). Furthermore, elevated IL13RA2 gene expression was seen in pHGG compared to low-grade CNS tumors (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). To validate these findings further, we assessed tissue expression of IL13RA2 in twenty post-mortem pediatric DIPG samples using immunohistochemistry (IHC). Nine of the twenty (45%) samples were positive for IL13RA2, receiving histopathological scores of 1 (n\u0026thinsp;=\u0026thinsp;5), 2 (n\u0026thinsp;=\u0026thinsp;3), and 3 (n\u0026thinsp;=\u0026thinsp;1) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u0026amp;C).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eGeneration and characterization of the RCAS-Tva model of high-grade pediatric diffuse glioma expressing IL13RA2\u003c/h2\u003e \u003cp\u003eTo generate \u003cem\u003ede novo\u003c/em\u003e tumors, we first cloned human IL13RA2 in a PDGFB construct using a T2A cleaving peptide. Next, we transfected DF-1 cells with either RCAS-Cre, RCAS-PDGFB, or RCAS-PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2 constructs. Subsequent flow cytometry (FSC) analysis of DF-1 cells showed robust expression of PDGFB (64.1%) and PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2 (64.0%) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). Secondary confirmation of successful RCAS-PDGFB and RCAS-PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2 transfection was achieved via western blotting for PDGFB and IL13RA2 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). Following transduction confirmation, we evaluated growth dynamics of de novo tumors \u003cem\u003ein vivo\u003c/em\u003e by infecting nestin-expressing progenitors in either the midbrain or right cortex of 4\u0026ndash;5-day-old Nestin-tva p53\u003csup\u003efl/fl\u003c/sup\u003e mice to model pDMG and pHGG, respectively. No significant changes were noted in the median survival of mice between RCAS-PDGFB (n\u0026thinsp;=\u0026thinsp;35, 38 days) and RCAS-PDGFB\u0026thinsp;+\u0026thinsp;IL13RA2 (n\u0026thinsp;=\u0026thinsp;35, 38 days) of pDMG models (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD).\u003c/p\u003e \u003cp\u003e \u003cem\u003eHistopathological analysis of\u003c/em\u003e de novo \u003cem\u003etumors, generation of cell lines, and orthotopic transplantation\u003c/em\u003e\u003c/p\u003e \u003cp\u003eTo further evaluate the recapitulation of our GEM model to pediatric tumors in humans, we performed IHC analysis for various markers. Both pDMG models (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA) and pHGG models (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB) revealed similar characteristics to post-mortem patient samples,\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e with noticeable cellular atypia, microvascular proliferation, and pseudopalisading necrosis in \u003cem\u003ede novo\u003c/em\u003e tumors (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA and B). Molecular characteristics of pDMG were present in both GEM models, with a cellular invasion of adjacent parenchyma, Ki67 positivity, Olig-2 expression, the presence of CD11b\u0026thinsp;+\u0026thinsp;cells, low number of CD3\u0026thinsp;+\u0026thinsp;cell, and heterogeneous IL13RA2 expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA and B).\u003c/p\u003e \u003cp\u003eIn order to develop targeted immunotherapies using these models, we generated cell lines from our \u003cem\u003ede novo\u003c/em\u003e tumors for subsequent \u003cem\u003ein vitro\u003c/em\u003e experiments. Brain tissue from tumor-bearing animals was processed in a single-cell suspension as described in the Material and Methods, placed into culture, and maintained as neurospheres. The expression of PDGFB and IL13RA2 was confirmed by both midline and cortical tumors by FSC analysis (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). To assess tumorigenicity, we orthotopically implanted these cell lines into the midline or right cortex of 4\u0026ndash;5 days-old Nestin-tva p53\u003csup\u003efl/fl\u003c/sup\u003e mice. Survival analysis displayed a median survival of 42 and 41 days for midline and cortical tumor-bearing, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD). IHC analysis of these tumors displayed histological features similar to those of \u003cem\u003ede novo\u003c/em\u003e tumors, with heterogeneous IL13RA2 expression, Olig-2 expression, infiltration of CD11b\u0026thinsp;+\u0026thinsp;cells, and a small number of CD3\u0026thinsp;+\u0026thinsp;cells along with Ki67- positivity (Suppl. Figure\u0026nbsp;1A).\u003c/p\u003e \u003cp\u003eThe genomic landscape of pHGG is characterized by recurrent mutations in TP53, PTEN, and histone H3 variant H3.3 (H3F3A)\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. In addition to Nestin-tva p53\u003csup\u003efl/fl\u003c/sup\u003e mice, we induced PTEN deletion into tumors using Nestin-tva p53\u003csup\u003efl/fl\u003c/sup\u003ePTEN\u003csup\u003efl/fl\u003c/sup\u003e mice and introduced the H3.3K27M mutation. Immunohistological evaluation of PTEN expression in both models confirmed deletion of PTEN in p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN\u003csup\u003efl/fl\u003c/sup\u003e, but not p53\u003csup\u003efl/fl\u003c/sup\u003e mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). Similarly, staining with an antibody detecting H3K27me3 revealed absence of staining in tumors with H3.3K27M mutation, with an exception for cells of tumor microenvironment or surrounding brain. Dual deletion of PTEN and p53 and dual deletion of PTEN and p53 with H3.3K27M generated significantly more aggressive tumors compared to p53 alone, with a median survival of mice of 31.0, 35.0, and 52.5 days in p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN\u003csup\u003efl/fl\u003c/sup\u003e and p53\u003csup\u003efl/fl\u003c/sup\u003e, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF). No difference in survival was seen upon introduction of the H3.3K27M compared to PTEN and p53 dual deletion (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003e \u003cem\u003eResponse of de novo tumors to CAR T- cell therapy\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eTo investigate the suitability of our GEM model of pHGG to targeted therapy, we generated murine IL13RA2-CAR T-cells, as described previously.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e The neurospheres of glioma cells established from cortical (Suppl. Figure\u0026nbsp;1B, C, D, and E) and midline tumors (Suppl. Figure\u0026nbsp;1F, G, H, and I) were labeled with CFSE, co-cultured with control non-transduced (NT) or CAR T-cells (CAR), and then characterized via flow cytometric analysis (gating strategy Suppl. Figure\u0026nbsp;2A and B). Both models demonstrated a significant response to CAR T-cells (Suppl. Figure\u0026nbsp;1C, Suppl. Figure\u0026nbsp;1G), with target-dependent activation of CD8+ (Suppl. Figure\u0026nbsp;1D, Suppl. Figure\u0026nbsp;1H) and CD4+ (Suppl. Figure\u0026nbsp;1E, Suppl. Figure\u0026nbsp;1I) CAR T-cells as judged by expression of CD25 and CD69 markers. Following confirmation of functionality, we tested the response to targeted therapy \u003cem\u003ein vivo\u003c/em\u003e by treating cortical tumor-bearing mice with CAR T-cell therapy. Intracranial delivery of CAR T-cells significantly improved the survival (MS: 46 days) compared to both saline (MS: 28 days), and NT-treated animals (MS: 31 days) (Wald p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). Furthermore, 25% of mice (3 out of 12) treated with CAR T-cells survived long-term (LTS) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA), and histological analysis confirmed absence of tumor in these mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB). To understand how targeted therapy effects TME cellular composition, we again treated cortical tumor-bearing mice (Suppl Fig.\u0026nbsp;1A) with CAR T cell therapy, harvested and processed the brains of CAR T-cell (CAR), non-transduced T-cell (NT), and saline treated animals into single cell suspensions, and performed multicolor flow cytometric analyses (gating strategy Suppl. Figure\u0026nbsp;2C). We observed significantly increased frequency of monocytic MDSC (M-MDSC; CD45\u003csup\u003e+\u003c/sup\u003eCD11b\u003csup\u003e+\u003c/sup\u003eLy6C\u003csup\u003e+\u003c/sup\u003eLy6G\u003csup\u003elo\u003c/sup\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC) and frequency of CD8 T-cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD), but not CD4 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE), in the brains of CAR T cell treated animals comapred to saline. We observed no change in the frequency in T regulatory cells (CD45\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003eFOXP3\u003csup\u003e+\u003c/sup\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF). Furthermore, we also observed increased frequency of activated (CD45\u003csup\u003e+\u003c/sup\u003eCD8\u003csup\u003e+\u003c/sup\u003eCD44\u003csup\u003e+\u003c/sup\u003eCD69\u003csup\u003e+\u003c/sup\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG) and cytotoxic (CD45\u003csup\u003e+\u003c/sup\u003eCD8\u003csup\u003e+\u003c/sup\u003eGZMB\u003csup\u003e+\u003c/sup\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eH) CD8 T-cells in CAR treated animals compared to saline. Together, these experiments indicate that \u003cem\u003ede novo\u003c/em\u003e established aggressive glioma tumors expressing IL13RA2 are responsive to CAR T-cell therapy, and thus, are suitable for investigating responses and resistance of aggressive pediatric diffuse gliomas to targeted therapeutics in mice with fully competent immune system.\u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eAmongst many factors, the efficacy of targeted immunotherapy depends on the targeted antigen's validity. IL13RA2 is an attractive TAA present in several CNS tumors and has been validated as an immunotherapeutic target in adult GBM\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. To better understand IL13RA2 as a potential immunotherapeutic target in the context of pHGG, we first characterized its expression in datasets of patient tissue samples. We found that IL13RA2 is expressed at higher levels in pHGG, notably with around 45% of DIPG samples expressing IL13RA2, an observation in agreement with other reports\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. These preliminary results suggest that IL13RA2 has the potential to be used as an immunotherapeutic target for pDMG and pHGG.\u003c/p\u003e \u003cp\u003eA significant obstacle to developing targeted immunotherapy for pDMG and pHGG is the lack of an immunocompetent model expressing human antigens. We used the RCAS-Tva system to overcome this limitation and induce \u003cem\u003ede novo\u003c/em\u003e tumorigenesis in immunocompetent mice. In doing so, we successfully generated pDMG and pHGG that express IL13RA2, and the addition of IL13RA2 to PDGFB-driven gliomas did not significantly impact the survival compared to the previously described PDGFB-driven tumor model of pediatric diffuse midline glioma\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. Moreover, \u003cem\u003ede novo\u003c/em\u003e tumors with a dual p53/PTEN deletion acquired a more aggressive phenotype than tumors with p53 deletion alone. Finally, our generated tumors recapitulated the histological and molecular hallmarks seen in patient samples, such as cellular atypia, microvascular proliferation, pseudo palisading necrosis, and invasion into surrounding brain tissue.\u003c/p\u003e \u003cp\u003eTumor-derived cell lines derived express IL13RA2 and reliably developed tumors when implanted orthotopically in the murine brain. Consistent with human pDMG and pHGG \u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e,\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e, both \u003cem\u003ede novo\u003c/em\u003e and orthotopically generated tumors displayed a heterogeneous expression of IL13RA2 with limited infiltration CD3 T-cells and a moderate CD11b myeloid cells in the TME. Our analysis of tumor-infiltrating T-cells and myeloid cells following CAR T-cell therapy revealed increased frequency of CD8 T-cells and monocytic MDSCs (M-MDSCs). M-MDSCs are normally recruited to sites of inflammation to help modulate immune responses and prevent excessive tissue damage. Once there, they can actively suppress T-cell response by expressing high levels of immunosuppressive molecules such as ARG1 and iNOS. Given the increased presence of tumor-infiltrating activated/cytotoxic CD8 T-cells following CAR T-cell treatment, a role of M-MDSC in supporting or dampening the tumor responses to CAR T-cells needs to be further investigated. Future studies employing single-cell RNA sequencing and multiplex immunofluorescence to characterize the TME will help to understand the changes taking place upon the introduction of immunotherapy and how these changes play a role in immunotherapeutic efficacy.\u003c/p\u003e \u003cp\u003eMultiple recurrent mutations characterize the genomic landscape of pHGG. TP53 mutations, affecting the well-studied tumor suppressor protein p53, occur in over 40% of patients \u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. PTEN mutations are present in 10\u0026ndash;20% of pHGG cases \u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. The most common mutation is in H3F3A, the gene encoding histone H3 variant H3.3. This mutation involves a lysine-to-methionine substitution at position 27 (H3.3K27M) and occurs in 70\u0026ndash;80% of cases \u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. Furthermore, a strong positive correlation between IL13RA2 expression and H3.3K27M mutation has been found in pHGG and pDMG \u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. In this study, we successfully used the RCAS-Tva model to generate H3.3K27M mutant tumors lacking p53 and PTEN that express IL13RA2. Furthermore, we demonstrate that \u003cem\u003ede novo\u003c/em\u003e IL13RA2-expressing tumors respond to CAR T-cell therapy, with some animals surviving long term. The strength of the GEM model is its versatility in incorporating molecular alterations, and this work serves as a proof of concept that relevant human antigens can be readily incorporated into GEM models and may serve as useful preclinical tools.\u003c/p\u003e \u003cp\u003eClinical studies using dual and multispecific targeting approaches have emerged in recent years. There is currently one clinical study using B7-H3-IL13RA2-CAR T cells in pediatric diffuse gliomas (NCT06221553); Another clinical study featuring a quad-specific B7H3-HER2-EGFR-IL13RA2 CAR T-cell in pediatric diffuse gliomas (NCT05768880). By incorporating additional human tumor-associated antigens (e.g., B7-H3, EGFRvIII, GD2, and HER2), this model could strengthen multi-targeting approaches for pediatric diffuse gliomas by enabling preclinical development in an immunocompetent host.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eWe developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, IL13RA2 and demonstrated the suitability of the model for evaluation of targeted therapy such as CAR T cells. We envision that this model will permit preclinical assessment of several human antigen-targeting immunotherapeutics, including CAR-T cells, bi- or multispecific T and NK cells engaging antibodies, and antibody-drug conjugates therapies within an immunocompetent host. After establishing the potential anti-tumor effect of each of these therapies, combinatorial approaches with concurrent radiation, chemotherapy, or targeted therapies, or in conjunction with other immunotherapeutic approaches, such as checkpoint inhibitors or other antibodies, will be considered. A robust evaluation of such strategies will allow for potential clinical translation to improve the outcome for children impacted by these devastating tumors.\u003c/p\u003e "},{"header":"Abbreviations","content":"\u003cp\u003eARG1 - Arginase 1\u003c/p\u003e\n\u003cp\u003eBCA - Bicinchoninic Acid\u003c/p\u003e\n\u003cp\u003eCAR T-cells - Chimeric Antigen Receptor-Modified T-Cells\u003c/p\u003e\n\u003cp\u003eCNS - Central Nervous System\u003c/p\u003e\n\u003cp\u003eDMEM - Dulbecco\u0026rsquo;s Modified Eagle\u0026rsquo;s Medium\u003c/p\u003e\n\u003cp\u003eDMG - Diffuse Midline Gliomas\u003c/p\u003e\n\u003cp\u003eDIPG - Diffuse Intrinsic Pontine Glioma\u003c/p\u003e\n\u003cp\u003eFBS - Fetal Bovine Serum\u003c/p\u003e\n\u003cp\u003eFSC - Flow Cytometry\u003c/p\u003e\n\u003cp\u003eGAPDH - Glyceraldehyde 3-Phosphate Dehydrogenase\u003c/p\u003e\n\u003cp\u003eGEMM - Genetically Engineered Mouse Model\u003c/p\u003e\n\u003cp\u003eGZMB - Granzyme B\u003c/p\u003e\n\u003cp\u003eH3F3A - Histone H3 Variant H3.3\u003c/p\u003e\n\u003cp\u003eH\u0026amp;E - Hematoxylin and Eosin\u003c/p\u003e\n\u003cp\u003eHSD - Honest Significant Difference\u003c/p\u003e\n\u003cp\u003eIACUC - Institutional Animal Care and Use Committee\u003c/p\u003e\n\u003cp\u003eIL13RA2 - Interleukin 13 Receptor Alpha 2\u003c/p\u003e\n\u003cp\u003eIHC - Immunohistochemistry\u003c/p\u003e\n\u003cp\u003eiNOS - Inducible Nitric Oxide Synthase\u003c/p\u003e\n\u003cp\u003eLTS - Long-Term Survival\u003c/p\u003e\n\u003cp\u003eM-MDSCs \u0026ndash; Monocytic \u0026nbsp; Myeloid-Derived Supressor Cells\u003c/p\u003e\n\u003cp\u003emPER - Mammalian Protein Extraction Reagent\u003c/p\u003e\n\u003cp\u003eNFDM - Non-Fat Dry Milk\u003c/p\u003e\n\u003cp\u003ePBS - Phosphate-Buffered Saline\u003c/p\u003e\n\u003cp\u003ePFA - Paraformaldehyde\u003c/p\u003e\n\u003cp\u003epDMG - Pediatric Diffuse Midline Gliomas\u003c/p\u003e\n\u003cp\u003epHGG - Pediatric High-Grade Glioma\u003c/p\u003e\n\u003cp\u003eT:E - Target-to-Effector\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eETHICS DECLARATIONS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eN/A\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIrina Balyasnikova is an inventor of a single-chain antibody targeting IL13RA2 and the CAR construct used in this study. All other authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHuman tumor samples were initially obtained under Institutional Review Board approved protocol (#IRB 2019-3164)\u0026nbsp;per Ann and Robert H. Lurie Children\u0026apos;s Hospital of Chicago. All animal studies were approved by the Northwestern University Institutional Animal Care and Use Committee (IACUC).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eFUNDING\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was supported in part by NINDS R01NS106379 (IVB) and R01NS122395 (IVB) grants and the Washington Square Health Foundation (MS). This study was supported in part by NINDS R01NS106379 (IVB) and R01NS122395 (IVB) grants and the Washington Square Health Foundation (MS). Histology services were provided by the Northwestern University Mouse Histology and Phenotyping Laboratory, which is supported by National Cancer Institute Grant P30-CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. In addition, this work was supported by the Northwestern University \u0026ndash; Flow Cytometry Core Facility supported by the Cancer Center Support Grant (NCI CA060553). The Northwestern Nervous System Tumor Bank is supported by the P50CA221747 SPORE for Translational Approaches to Brain Cancer.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eACKNOWLEDGEMENTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors thank Liliana Ilut and Quanli Liu for their technical assistance in initial stages of the project.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMackay, A.\u003cem\u003e et al.\u003c/em\u003e Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. \u003cem\u003eCancer Cell\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 520-537 e525 (2017). https://doi.org:10.1016/j.ccell.2017.08.017\u003c/li\u003e\n\u003cli\u003eWarren, K. E.\u003cem\u003e et al.\u003c/em\u003e Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. \u003cem\u003eNeuro Oncol\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 326-332 (2012). https://doi.org:10.1093/neuonc/nor190\u003c/li\u003e\n\u003cli\u003eFoster, J. B.\u003cem\u003e et al.\u003c/em\u003e Immunotherapy for pediatric brain tumors: past and present. \u003cem\u003eNeuro Oncol\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 1226-1238 (2019). https://doi.org:10.1093/neuonc/noz077\u003c/li\u003e\n\u003cli\u003eBerlow, N. E.\u003cem\u003e et al.\u003c/em\u003e IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, e0193565 (2018). https://doi.org:10.1371/journal.pone.0193565\u003c/li\u003e\n\u003cli\u003eSchwartzentruber, J.\u003cem\u003e et al.\u003c/em\u003e Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. \u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e482\u003c/strong\u003e, 226-231 (2012). https://doi.org:10.1038/nature10833\u003c/li\u003e\n\u003cli\u003eWu, G.\u003cem\u003e et al.\u003c/em\u003e Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. \u003cem\u003eNat Genet\u003c/em\u003e \u003cstrong\u003e44\u003c/strong\u003e, 251-253 (2012). https://doi.org:10.1038/ng.1102\u003c/li\u003e\n\u003cli\u003eKhuong-Quang, D. A.\u003cem\u003e et al.\u003c/em\u003e K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. \u003cem\u003eActa Neuropathol\u003c/em\u003e \u003cstrong\u003e124\u003c/strong\u003e, 439-447 (2012). https://doi.org:10.1007/s00401-012-0998-0\u003c/li\u003e\n\u003cli\u003eHaydar, D.\u003cem\u003e et al.\u003c/em\u003e Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. \u003cem\u003eNeuro Oncol\u003c/em\u003e \u003cstrong\u003e23\u003c/strong\u003e, 999-1011 (2021). https://doi.org:10.1093/neuonc/noaa278\u003c/li\u003e\n\u003cli\u003eMount, C. W.\u003cem\u003e et al.\u003c/em\u003e Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. \u003cem\u003eNat Med\u003c/em\u003e \u003cstrong\u003e24\u003c/strong\u003e, 572-579 (2018). https://doi.org:10.1038/s41591-018-0006-x\u003c/li\u003e\n\u003cli\u003eMajzner, R. G.\u003cem\u003e et al.\u003c/em\u003e CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. \u003cem\u003eClin Cancer Res\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 2560-2574 (2019). https://doi.org:10.1158/1078-0432.CCR-18-0432\u003c/li\u003e\n\u003cli\u003eTheruvath, J.\u003cem\u003e et al.\u003c/em\u003e Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. \u003cem\u003eNat Med\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 712-719 (2020). https://doi.org:10.1038/s41591-020-0821-8\u003c/li\u003e\n\u003cli\u003eLian, X.\u003cem\u003e et al.\u003c/em\u003e Design considerations of an IL13Ralpha2 antibody-drug conjugate for diffuse intrinsic pontine glioma. \u003cem\u003eActa Neuropathol Commun\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 88 (2021). https://doi.org:10.1186/s40478-021-01184-9\u003c/li\u003e\n\u003cli\u003eOkada, H.\u003cem\u003e et al.\u003c/em\u003e Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. \u003cem\u003eJ Neurooncol\u003c/em\u003e \u003cstrong\u003e88\u003c/strong\u003e, 245-250 (2008). https://doi.org:10.1007/s11060-008-9566-9\u003c/li\u003e\n\u003cli\u003ePollack, I. F.\u003cem\u003e et al.\u003c/em\u003e Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. \u003cem\u003eJ Clin Oncol\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 2050-2058 (2014). https://doi.org:10.1200/JCO.2013.54.0526\u003c/li\u003e\n\u003cli\u003eBrown, C. E.\u003cem\u003e et al.\u003c/em\u003e Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. \u003cem\u003eNat Med\u003c/em\u003e (2024). https://doi.org:10.1038/s41591-024-02875-1\u003c/li\u003e\n\u003cli\u003eMisuraca, K. L., Cordero, F. J. \u0026amp; Becher, O. J. Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. \u003cem\u003eFront Oncol\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, 172 (2015). https://doi.org:10.3389/fonc.2015.00172\u003c/li\u003e\n\u003cli\u003eLarson, J. D.\u003cem\u003e et al.\u003c/em\u003e Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. \u003cem\u003eCancer Cell\u003c/em\u003e \u003cstrong\u003e35\u003c/strong\u003e, 140-155 e147 (2019). https://doi.org:10.1016/j.ccell.2018.11.015\u003c/li\u003e\n\u003cli\u003eHolland, E. C., Hively, W. P., DePinho, R. A. \u0026amp; Varmus, H. E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. \u003cem\u003eGenes Dev\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 3675-3685 (1998). https://doi.org:10.1101/gad.12.23.3675\u003c/li\u003e\n\u003cli\u003eHaag, D.\u003cem\u003e et al.\u003c/em\u003e H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. \u003cem\u003eCancer Cell\u003c/em\u003e \u003cstrong\u003e39\u003c/strong\u003e, 407-422 e413 (2021). https://doi.org:10.1016/j.ccell.2021.01.005\u003c/li\u003e\n\u003cli\u003eLewis, P. W.\u003cem\u003e et al.\u003c/em\u003e Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. \u003cem\u003eScience\u003c/em\u003e \u003cstrong\u003e340\u003c/strong\u003e, 857-861 (2013). https://doi.org:10.1126/science.1232245\u003c/li\u003e\n\u003cli\u003eBecher, O. J.\u003cem\u003e et al.\u003c/em\u003e Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. \u003cem\u003eCancer Res\u003c/em\u003e \u003cstrong\u003e70\u003c/strong\u003e, 2548-2557 (2010). https://doi.org:10.1158/0008-5472.CAN-09-2503\u003c/li\u003e\n\u003cli\u003ePituch, K. C.\u003cem\u003e et al.\u003c/em\u003e Adoptive Transfer of IL13Ralpha2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. \u003cem\u003eMol Ther\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 986-995 (2018). https://doi.org:10.1016/j.ymthe.2018.02.001\u003c/li\u003e\n\u003cli\u003ePituch, K. C.\u003cem\u003e et al.\u003c/em\u003e Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e118\u003c/strong\u003e (2021). https://doi.org:10.1073/pnas.2015800118\u003c/li\u003e\n\u003cli\u003eGump, J. M.\u003cem\u003e et al.\u003c/em\u003e Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. \u003cem\u003eActa Neuropathol Commun\u003c/em\u003e \u003cstrong\u003e3\u003c/strong\u003e, 30 (2015). https://doi.org:10.1186/s40478-015-0211-5\u003c/li\u003e\n\u003cli\u003eRoss, J. L.\u003cem\u003e et al.\u003c/em\u003e Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e144\u003c/strong\u003e, 53-69 (2021). https://doi.org:10.1093/brain/awaa382\u003c/li\u003e\n\u003cli\u003eZannikou, M.\u003cem\u003e et al.\u003c/em\u003e IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. \u003cem\u003eJ Immunother Cancer\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e (2023). https://doi.org:10.1136/jitc-2022-006239\u003c/li\u003e\n\u003cli\u003eHeiss, J. D.\u003cem\u003e et al.\u003c/em\u003e Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. \u003cem\u003eJ Neurosurg Pediatr\u003c/em\u003e \u003cstrong\u003e23\u003c/strong\u003e, 333-342 (2018). https://doi.org:10.3171/2018.9.PEDS17225\u003c/li\u003e\n\u003cli\u003eBrown, C. E.\u003cem\u003e et al.\u003c/em\u003e Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. \u003cem\u003eN Engl J Med\u003c/em\u003e \u003cstrong\u003e375\u003c/strong\u003e, 2561-2569 (2016). https://doi.org:10.1056/NEJMoa1610497\u003c/li\u003e\n\u003cli\u003eJones, C.\u003cem\u003e et al.\u003c/em\u003e Pediatric high-grade glioma: biologically and clinically in need of new thinking. \u003cem\u003eNeuro Oncol\u003c/em\u003e \u003cstrong\u003e19\u003c/strong\u003e, 153-161 (2017). https://doi.org:10.1093/neuonc/now101\u003c/li\u003e\n\u003cli\u003eSchwartzentruber, J.\u003cem\u003e et al.\u003c/em\u003e Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. \u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e482\u003c/strong\u003e, 226-231 (2012). https://doi.org:10.1038/nature10833\u003c/li\u003e\n\u003cli\u003eDebinski, W. \u0026amp; Gibo, D. M. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. \u003cem\u003eMol Med\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 440-449 (2000). \u003c/li\u003e\n\u003cli\u003eDebinski, W., Slagle, B., Gibo, D. M., Powers, S. K. \u0026amp; Gillespie, G. Y. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. \u003cem\u003eJ Neurooncol\u003c/em\u003e \u003cstrong\u003e48\u003c/strong\u003e, 103-111 (2000). https://doi.org:10.1023/a:1006446426611\u003c/li\u003e\n\u003cli\u003eCordero, F. J.\u003cem\u003e et al.\u003c/em\u003e Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG. \u003cem\u003eMol Cancer Res\u003c/em\u003e \u003cstrong\u003e15\u003c/strong\u003e, 1243-1254 (2017). https://doi.org:10.1158/1541-7786.MCR-16-0389\u003c/li\u003e\n\u003cli\u003ePlant, A. S.\u003cem\u003e et al.\u003c/em\u003e Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. \u003cem\u003eJ Neurooncol\u003c/em\u003e \u003cstrong\u003e137\u003c/strong\u003e, 269-278 (2018). https://doi.org:10.1007/s11060-017-2737-9\u003c/li\u003e\n\u003cli\u003eLieberman, N. A. P.\u003cem\u003e et al.\u003c/em\u003e Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. \u003cem\u003eNeuro Oncol\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 83-94 (2019). https://doi.org:10.1093/neuonc/noy145\u003c/li\u003e\n\u003cli\u003eWu, G.\u003cem\u003e et al.\u003c/em\u003e The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. \u003cem\u003eNature Genetics\u003c/em\u003e \u003cstrong\u003e46\u003c/strong\u003e, 444-450 (2014). https://doi.org:10.1038/ng.2938\u003c/li\u003e\n\u003cli\u003eKhuong-Quang, D.-A.\u003cem\u003e et al.\u003c/em\u003e K27M mutation in histone H3. 3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. \u003cem\u003eActa neuropathologica\u003c/em\u003e \u003cstrong\u003e124\u003c/strong\u003e, 439-447 (2012). \u003c/li\u003e\n\u003cli\u003eDeng, H.\u003cem\u003e et al.\u003c/em\u003e Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma. \u003cem\u003eMolecular Cancer Research\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e, 623-633 (2018). https://doi.org:10.1158/1541-7786.mcr-17-0460\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"acta-neuropathologica-communications","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"anec","sideBox":"Learn more about [Acta Neuropathologica Communications](https://actaneurocomms.biomedcentral.com/)","snPcode":"40478","submissionUrl":"https://submission.springernature.com/new-submission/40478/3","title":"Acta Neuropathologica Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-5398280/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5398280/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003ePediatric high-grade gliomas (pHGG) and pediatric diffuse midline gliomas (pDMG) are devastating diseases without durable and curative options. Although targeted immunotherapy has shown promise, the field lacks immunocompetent animal models to study these processes in detail. To achieve this, we developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, interleukin 13 receptor alpha 2 (IL13RA2). Utilizing the RCAS-Tva delivery system in Nestin-Tva mice, we induced gliomagenesis by overexpressing PDGFB and deleting p53 (p53\u003csup\u003efl/fl\u003c/sup\u003e) or both p53 and PTEN (p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN\u003csup\u003efl/fl\u003c/sup\u003e), with or without IL13RA2 in neonatal mice. \u003cem\u003eDe novo\u003c/em\u003e tumors developed in models with and without IL13RA2, showing no statistical difference in onset (n\u0026thinsp;=\u0026thinsp;33, 38 days, p\u0026thinsp;=\u0026thinsp;0.62). The p53\u003csup\u003efl/fl\u003c/sup\u003e PTEN\u003csup\u003efl/fl\u003c/sup\u003e tumors displayed more aggressive characteristics (n\u0026thinsp;=\u0026thinsp;12, 31 days). Tumors exhibited features typical of high-grade glioma, including infiltration, pseudopalisading necrosis, and microvascular proliferation. They also showed a high Ki-67 index, variable IL13RA2 expression, a high frequency of CD11b\u0026thinsp;+\u0026thinsp;macrophages, and a low proportion of CD3\u0026thinsp;+\u0026thinsp;T cells. The model proved effective for evaluating IL13RA2-targeted immunotherapies, with a significant response to CAR T-cell treatment that extended survival (46 days vs. 28 days control; p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and achieved 25% long-term survival in mice. This model facilitates the preclinical assessment of IL13RA2-directed therapies and holds potential for clinical application.\u003c/p\u003e","manuscriptTitle":"IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-12-11 19:12:15","doi":"10.21203/rs.3.rs-5398280/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-12-27T19:40:27+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-12-11T20:41:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"223584471910777465822707528216827536686","date":"2024-11-25T06:44:17+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-11-20T14:51:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-11-13T14:21:28+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-11-13T14:21:23+00:00","index":"","fulltext":""},{"type":"submitted","content":"Acta Neuropathologica Communications","date":"2024-11-05T22:50:54+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"acta-neuropathologica-communications","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"anec","sideBox":"Learn more about [Acta Neuropathologica Communications](https://actaneurocomms.biomedcentral.com/)","snPcode":"40478","submissionUrl":"https://submission.springernature.com/new-submission/40478/3","title":"Acta Neuropathologica Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"6a18d314-e326-4fa3-a7a6-6732568b4af1","owner":[],"postedDate":"December 11th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-04-07T16:08:12+00:00","versionOfRecord":{"articleIdentity":"rs-5398280","link":"https://doi.org/10.1186/s40478-025-01991-4","journal":{"identity":"acta-neuropathologica-communications","isVorOnly":false,"title":"Acta Neuropathologica Communications"},"publishedOn":"2025-04-02 15:57:10","publishedOnDateReadable":"April 2nd, 2025"},"versionCreatedAt":"2024-12-11 19:12:15","video":"","vorDoi":"10.1186/s40478-025-01991-4","vorDoiUrl":"https://doi.org/10.1186/s40478-025-01991-4","workflowStages":[]},"version":"v1","identity":"rs-5398280","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5398280","identity":"rs-5398280","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}